FLJ21062 Inhibitors
FLJ21062 inhibitors represent a distinct chemical class specifically designed to interact with and inhibit the activity of the FLJ21062 protein. The inhibitory action of these compounds is highly targeted, affecting the FLJ21062 protein's function by disrupting its specific signaling pathways and biological processes. Each inhibitor within this class is characterized by its chemical structure and mode of action, which directly correlates with the reduction in FLJ21062 activity. The inhibitors may achieve this by binding to the active site of the protein, preventing its interaction with substrates or cofactors essential for its function. Alternatively, they may interact with regulatory regions of the protein, altering its conformation and thereby impeding its activity. The precision of these inhibitors lies in their ability to selectively influence the FLJ21062 protein without broadly affecting other proteins or pathways. This specificity ensures a targeted approach to inhibition, where only the pathways involving FLJ21062 are affected.
The biochemical pathways influenced by FLJ21062 inhibitors are integral to understanding their mechanism of action. While the exact biological role of FLJ21062 may encompass a range of functions, the inhibitors are designed to impact the protein's contribution to these pathways negatively. By doing so, they effectively reduce the functional output of FLJ21062, leading to a decrease in its associated activities. The chemical compounds within this class are varied, yet they share the common feature of having a significant influence on the protein's activity. The complex interaction between FLJ21062 inhibitors and the protein's signaling pathways exemplifies the intricate nature of protein function regulation within the cell. These inhibitors are crucial tools for probing the biological role of FLJ21062 and offer insights into the fine-tuning of cellular processes that are mediated by this specific protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and specific inhibitor of phosphatidylinositol 3-kinase (PI3K), which is involved in the signaling pathways leading to cell growth, proliferation, and differentiation. FLJ21062 is dependent on the PI3K pathway for its activation; therefore, inhibition of PI3K by Wortmannin would lead to a decrease in FLJ21062 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and metabolism in response to environmental cues. Since mTOR signaling is crucial for the function and regulation of FLJ21062, the use of Rapamycin would result in decreased activity of FLJ21062 by inhibiting the pathway upstream of its activation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the Akt pathway, which is crucial for promoting cell survival and growth. The activity of FLJ21062 is regulated in part by Akt-mediated signaling, hence inhibiting Akt with Triciribine will lead to a reduction in FLJ21062 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K that prevents the phosphorylation and activation of downstream targets involved in cell proliferation and survival. By inhibiting the PI3K pathway, LY294002 would lead to decreased activation of FLJ21062. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 acts as a selective inhibitor of MEK, which is part of the MAPK/ERK pathway, a signaling pathway involved in the control of cell division and differentiation. Since FLJ21062 is indirectly regulated by the MAPK/ERK pathway, PD98059 would reduce its activity by blocking the pathway upstream. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is implicated in inflammatory responses and cell differentiation. By inhibiting p38 MAP kinase, SB203580 would indirectly decrease the functional activity of FLJ21062 if it is regulated by inflammatory signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 specifically inhibits MEK1/2, key enzymes in the MAPK/ERK signaling pathway. FLJ21062, which may be activated by this pathway, would have reduced activity in the presence of U0126 due to the inhibition of signaling upstream. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is involved in stress-activated protein kinase signaling pathways affecting cellular processes such as apoptosis and differentiation. As the JNK pathway can intersect with pathways regulating FLJ21062, inhibition by SP600125 could result in decreased activity of FLJ21062. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the regulation of cell survival and proliferation. If FLJ21062 activity is influenced by EGFR signaling, then inhibition by Gefitinib would lead to a decrease in its activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor, working similarly to Gefitinib. It blocks the transduction of signals critical for the proliferation and survival of tumor cells. Should FLJ21062 be part of the EGFR signaling network, Erlotinib would also contribute to the reduction of FLJ21062 activity. | ||||||